Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery

Authors: Takayoshi Kiba, Takashi Inamoto, Tsutomu Nishimura, Masaya Ueno, Kazuhiro Yanagihara, Satoshi Teramukai, Hironori Kato, Masakazu Toi, Masanori Fukushima

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Backgrounds

Prognostic factors are defined as biological or clinical measurement associated with overall survival and/or disease-free survival. Previous studies have shown that patients with estrogen receptor (ER) positive cancers have a better prognosis than patients whose cancers do not have these receptors.

Methods

This study investigated the assessment of variables in defining prognosis of 742 breast cancer women with pathological stage (pTNM) I-III diagnosed between 1980 and 2005 at the Kyoto University Hospital in Japan, by age, clinical stage (cTNM), pTNM, the numbers of positive lymph nodes (pN), and ER status.

Results

Multivariate analysis demonstrated that pTNM and ER status were the independent prognostic factors for overall survival, and that pTNM and pN were the independent prognostic factors for disease-free survival. For the 0- to 2-year interval, the hazard of recurrence was higher for the ER-negative patients than the ER-positive patients, and beyond 3 years the hazard was higher for ER-positive patients.

Conclusion

The present study confirmed the previous reports which showed favorable prognosis of the patients with lesser pTNM or positive ER status. A reversal of recurrence hazard rate between ER positive and negative breast cancer patients beyond 3 years after operation was detected. The fact may indicate the importance of long term adjuvant hormone therapy for ER positive cancer patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference DeVita VT, Hellman S, Rosenberg SA: Cancer: Principles and Practice of Oncology. 2001, Philadelphia: Lippincott Williams & Wilkins DeVita VT, Hellman S, Rosenberg SA: Cancer: Principles and Practice of Oncology. 2001, Philadelphia: Lippincott Williams & Wilkins
2.
go back to reference Gospodarowicz M, Mackillop W, O'Sullivan B, Sobin L, Henson D, Hutter RV, Wittekind C: Prognostic factors in clinical decision making: the future. Cancer. 2001, 91 (8 Suppl): 1688-1695. 10.1002/1097-0142(20010415)91:8+<1688::AID-CNCR1184>3.0.CO;2-7.CrossRefPubMed Gospodarowicz M, Mackillop W, O'Sullivan B, Sobin L, Henson D, Hutter RV, Wittekind C: Prognostic factors in clinical decision making: the future. Cancer. 2001, 91 (8 Suppl): 1688-1695. 10.1002/1097-0142(20010415)91:8+<1688::AID-CNCR1184>3.0.CO;2-7.CrossRefPubMed
3.
go back to reference Clark GM: Do we really need prognostic factors for breast cancer?. Breast Cancer Res Treat. 1994, 30 (2): 117-126. 10.1007/BF00666054.CrossRefPubMed Clark GM: Do we really need prognostic factors for breast cancer?. Breast Cancer Res Treat. 1994, 30 (2): 117-126. 10.1007/BF00666054.CrossRefPubMed
4.
go back to reference Hedden S, Woolson R, Malcolm R: Randomization in substance abuse clinical trials. Substance Abuse Treatment, Prevention, and Policy. 2006, 1 (6): 1-17. Hedden S, Woolson R, Malcolm R: Randomization in substance abuse clinical trials. Substance Abuse Treatment, Prevention, and Policy. 2006, 1 (6): 1-17.
5.
go back to reference Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18 (7): 1133-1144. 10.1093/annonc/mdm271.CrossRefPubMed Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18 (7): 1133-1144. 10.1093/annonc/mdm271.CrossRefPubMed
6.
go back to reference Ueno M, Kiba T, Nishimura T, Kitano T, Yanagihara K, Yoshikawa K, Ishiguro H, Teramukai S, Fukushima M, Kato H, Inamoto T: Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital. Eur J Surg Oncol. 2007, 33 (6): 696-699.CrossRefPubMed Ueno M, Kiba T, Nishimura T, Kitano T, Yanagihara K, Yoshikawa K, Ishiguro H, Teramukai S, Fukushima M, Kato H, Inamoto T: Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital. Eur J Surg Oncol. 2007, 33 (6): 696-699.CrossRefPubMed
7.
go back to reference Sobin LH, Wittekind CH: TNM Classification of malignant Tumors. 2002, New York: Wiley-Liss Sobin LH, Wittekind CH: TNM Classification of malignant Tumors. 2002, New York: Wiley-Liss
8.
go back to reference Pritchard KI: Prognostic and Predictive Factors for Breast Cancer. Proceedings of 26th Annual San Antonio Breast Cancer Symposium; December 3 – 6. 2003, , San Antonio Pritchard KI: Prognostic and Predictive Factors for Breast Cancer. Proceedings of 26th Annual San Antonio Breast Cancer Symposium; December 3 – 6. 2003, , San Antonio
9.
go back to reference Pritchard KI: The best use of adjuvant endocrine treatments. Breast. 2003, 12 (6): 497-508. 10.1016/S0960-9776(03)00160-7.CrossRefPubMed Pritchard KI: The best use of adjuvant endocrine treatments. Breast. 2003, 12 (6): 497-508. 10.1016/S0960-9776(03)00160-7.CrossRefPubMed
10.
go back to reference Pritchard KI: Adjuvant endocrine therapies for pre-/perimenopausal women. Breast. 2005, 14 (6): 547-554. 10.1016/j.breast.2005.09.002.CrossRefPubMed Pritchard KI: Adjuvant endocrine therapies for pre-/perimenopausal women. Breast. 2005, 14 (6): 547-554. 10.1016/j.breast.2005.09.002.CrossRefPubMed
11.
go back to reference Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H, Kimura M, Tominaga T, Iino H, Morimoto T, et al: Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the Study Group for the Japanese Breast Cancer Society on Hormone Receptors and Prognosis in Breast Cancer. Cancer. 1992, 69 (1): 153-164. 10.1002/1097-0142(19920101)69:1<153::AID-CNCR2820690127>3.0.CO;2-P.CrossRefPubMed Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H, Kimura M, Tominaga T, Iino H, Morimoto T, et al: Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the Study Group for the Japanese Breast Cancer Society on Hormone Receptors and Prognosis in Breast Cancer. Cancer. 1992, 69 (1): 153-164. 10.1002/1097-0142(19920101)69:1<153::AID-CNCR2820690127>3.0.CO;2-P.CrossRefPubMed
12.
go back to reference Hortobagyi GN, Kau SW, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, Valero V: What is the prognosis of patients with operable breast cancer five years after diagnosis?. Proc Am Soc Clin Oncol. 1994, 23: 585A- Hortobagyi GN, Kau SW, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, Valero V: What is the prognosis of patients with operable breast cancer five years after diagnosis?. Proc Am Soc Clin Oncol. 1994, 23: 585A-
13.
go back to reference Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996, 14 (10): 2738-2746.PubMed Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996, 14 (10): 2738-2746.PubMed
14.
go back to reference Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef
15.
go back to reference Swain SM: Tamoxifen: the long and short of it. J Natl Cancer Inst. 1996, 88 (21): 1510-1512. 10.1093/jnci/88.21.1516.CrossRefPubMed Swain SM: Tamoxifen: the long and short of it. J Natl Cancer Inst. 1996, 88 (21): 1510-1512. 10.1093/jnci/88.21.1516.CrossRefPubMed
Metadata
Title
The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery
Authors
Takayoshi Kiba
Takashi Inamoto
Tsutomu Nishimura
Masaya Ueno
Kazuhiro Yanagihara
Satoshi Teramukai
Hironori Kato
Masakazu Toi
Masanori Fukushima
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-323

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine